Shree Ganesh Remedies Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/as-381fc11c4a345074b1ceb069.pdf

Key Takeaways


Revenue Recovery & Headwinds

Gunjan Kothia: "Some of the projects we realized that we can use our existing chemistry to leverage the products that India does import from China and where we can still make a decent margin. So this was a quite strategic move."

Margin Dynamics


Pipeline & New Product Traction

Gunjan Kothia: "If the customer, our customer, finds an alternate vendor, they will need to go through this whole chain, and so the switching will be much more difficult."

Strategic Direction & Portfolio Reshaping

Gunjan Kothia: "In the future, most of our revenue would be from the CRAMs, either it be agrochemical or electronics or semiconductor. On the pharmaceutical, we are going a bit on a softer side, so majority of our revenue would be from agro and semiconductor. Followed by pharmaceutical as we move ahead."
Gunjan Kothia: "These innovative companies or these top-tier companies, they don't entertain unless and until they think the manufacturer is capable to deliver this product."

Capacity & Infrastructure Build-Out

Gunjan Kothia: "Wee are slowly putting up the blocks to cater to this new projects as and when required. ... we keep on expanding and putting up the infrastructure. And also, to talk about the available land parcel and land space, we have ample land space in Ankleshwar side. And so the construction will continue on the Ankleshwar site, and only if required, then it will be shifted to the Dahed site."

Balance Sheet & Working Capital


Guidance & Commitments

CommitmentSpecificsTimeline
Core business recoveryCore pharmaceutical intermediates business to recover to earlier levels, based on improved European customer traction and domestic focusNext few quarters
Margin normalizationMargins to normalize as sales return to earlier levels and input costs ease with geopolitical stabilizationNext few quarters
New products export expansionTake the2 new pharmaceutical intermediates (anti-diabetic, cardiovascular) to export marketsComing quarters
Southeast Asia CRAMS commercial supplyCommercial supplies to begin for the first specialty chemical projectQ1 FY28
CRAMS commercial supply clarityClarity on commercial supply for the CRAMS project expected; commercialization eventually starting in Q1 of next yearBy end of March (Q4 FY27)
CRAMS peak utilizationCRAMS projects expected to reach peak commercial quantities; at peak, plant utilization around80% in total at SGRIn3 years
Revenue doubling visibilitySame visibility that revenue can double with existing productsNext3–4 years
Inventory normalizationInventory and stock to return to normal levels as geopolitical situation and volatility calm downNext few quarters
Regulatory approvalPlanning to get up to WHO GMPIn pipeline (undated)

Key Metrics

MetricQ2 FY27
Revenue from operations₹23.29 cr, +62.62% QoQ and -23% YoY
EBITDA (excl. other income and exceptional items)₹3.94 cr, +17% QoQ and -59% YoY
EBITDA margin16.99%, vs 23.3% in Q1 FY27 and 31.7% in Q2 FY26
Profit after tax₹1.63 cr, +46% QoQ and -67% YoY
Earnings per share₹1.28
Operating expenses₹19.36 cr, +76% QoQ vs revenue growth of 62% QoQ
Total borrowings₹25.99 cr, down from ₹30.67 cr at end of March FY26
Cash and bank balances plus investments₹28.74 cr, higher than total borrowings
H1 FY27 cash from operating activities₹14.64 cr, vs ₹17.66 cr in H1 FY26
Trade receivables₹21.12 cr, down from ₹32.57 cr at end of March FY26
Capital work in progress₹16.6 cr, up from ₹12.38 cr at end of March FY26
H1 FY27 finance cost₹0.89 cr, down from ₹1.95 cr in H1 FY26
CRAMS projects in pipeline10+ projects across R&D, pilot, and commercial scale-up stages
Anticipated asset turnover on new investments~2 times
Anticipated payback period on new projects3 to 4 years from commercialization start
Internal ROCE benchmark20 to 25% (per an analyst's math, confirmed by management)